Literature DB >> 7489407

Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice.

E Bachar-Lustig1, N Rachamim, H W Li, F Lan, Y Reisner.   

Abstract

Graft-versus-host disease (GVHD) is uniformly lethal in recipients of HLA-mismatched marrow. In patients with severe combined immunodeficiency disease, this major obstacle can be overcome by rigorous T-cell depletion before transplantation. In leukaemia patients, however, the benefit of preventing GVHD is offset by graft rejection or graft failure. Very recently, this problem was overcome by supplementing T cell-depleted bone marrow transplants with megadoses of peripheral blood stem cells collected by leukapheresis after mobilization of the donor stem cells with granulocyte colony-stimulating factor (G-CSF). In the present study, we further demonstrate in a mouse model (C57BL/6-->C3H/Hej) that escalation of bone marrow doses by four- to fivefold leads to full donor-type chimerism in sublethally irradiated (6.5 Gy) recipients. Thus, the new source of G-CSF mobilized human haematopoietic stem cells may enable extending the use of mismatched bone marrow transplants to patients with non-malignant diseases for whom supralethal conditioning is not a prerequisite.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489407     DOI: 10.1038/nm1295-1268

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  56 in total

Review 1.  Tolerance induction for solid organ grafts with donor-derived hematopoietic reconstitution.

Authors:  K L Gandy
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning.

Authors:  Luis Graca; Stephen Daley; Paul J Fairchild; Stephen P Cobbold; Herman Waldmann
Journal:  BMC Immunol       Date:  2006-04-25       Impact factor: 3.615

Review 3.  Diverse clinical applications using advantages of allogeneic peripheral blood stem cell transplantation.

Authors:  Sang Kyun Sohn; Jong Gwang Kim; Dong Hwan Kim; Jin Ho Baek; Kyu Bo Lee
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 4.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

Review 5.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

Review 6.  Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.

Authors:  Loredana Ruggeri; Marusca Capanni; Antonella Mancusi; Katia Perruccio; Emanuela Burchielli; Massimo F Martelli; Andrea Velardi
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

7.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

Review 8.  Mixed hematopoietic chimerism and transplantation tolerance.

Authors:  B Nikolic; M Sykes
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

9.  Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.

Authors:  Steven M Kornblau; Preston G Aycox; Clifton Stephens; L David McCue; Richard E Champlin; Frank C Marini
Journal:  Exp Hematol       Date:  2007-05       Impact factor: 3.084

10.  Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Authors:  Johnnie J Orozco; Aimee Kenoyer; Ethan R Balkin; Ted A Gooley; Donald K Hamlin; D Scott Wilbur; Mark D Hylarides; Sofia H L Frost; Raya Mawad; Paul O'Donnell; Brenda M Sandmaier; Ephraim J Fuchs; Leo Luznik; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.